JANX Quote, Financials, Valuation and Earnings

Galectin Therapeutics has a net margin of -6391.57% compared to Janux Therapeutics's net margin of --. Janux Therapeutics's return on equity of -11.37% beat Galectin Therapeutics's return on equity of --.

Janux Therapeutics has a consensus price target of --, signalling upside risk potential of 66.1%. On the other hand Galectin Therapeutics has an analysts' consensus of -- which suggests that it could grow by 1164.22%. Given that Galectin Therapeutics has higher upside potential than Janux Therapeutics, analysts believe Galectin Therapeutics is more attractive than Janux Therapeutics.

Janux Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Galectin Therapeutics has a beta of 0.689, suggesting its less volatile than the S&P 500 by 31.07%.

Janux Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Galectin Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Janux Therapeutics pays -- of its earnings as a dividend. Galectin Therapeutics pays out -- of its earnings as a dividend.

Janux Therapeutics quarterly revenues are $439K, which are larger than Galectin Therapeutics quarterly revenues of --. Janux Therapeutics's net income of -$28.1M is lower than Galectin Therapeutics's net income of -$11.2M. Notably, Janux Therapeutics's price-to-earnings ratio is -- while Galectin Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Janux Therapeutics is 216.51x versus -- for Galectin Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Rezolute has a net margin of -6391.57% compared to Janux Therapeutics's net margin of --. Janux Therapeutics's return on equity of -11.37% beat Rezolute's return on equity of --.

Janux Therapeutics has a consensus price target of --, signalling upside risk potential of 66.1%. On the other hand Rezolute has an analysts' consensus of $9.67 which suggests that it could grow by 194.79%. Given that Rezolute has higher upside potential than Janux Therapeutics, analysts believe Rezolute is more attractive than Janux Therapeutics.

Janux Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Rezolute has a beta of 1.011, suggesting its more volatile than the S&P 500 by 1.093%.

Janux Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Rezolute offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Janux Therapeutics pays -- of its earnings as a dividend. Rezolute pays out -- of its earnings as a dividend.

Janux Therapeutics quarterly revenues are $439K, which are larger than Rezolute quarterly revenues of --. Janux Therapeutics's net income of -$28.1M is lower than Rezolute's net income of -$15.4M. Notably, Janux Therapeutics's price-to-earnings ratio is -- while Rezolute's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Janux Therapeutics is 216.51x versus -- for Rezolute. Usually stocks with elevated PS ratios are considered overvalued.

Spero Therapeutics has a net margin of -6391.57% compared to Janux Therapeutics's net margin of -219.3%. Janux Therapeutics's return on equity of -11.37% beat Spero Therapeutics's return on equity of 4.36%.

Janux Therapeutics has a consensus price target of --, signalling upside risk potential of 66.1%. On the other hand Spero Therapeutics has an analysts' consensus of $5.00 which suggests that it could grow by 433.33%. Given that Spero Therapeutics has higher upside potential than Janux Therapeutics, analysts believe Spero Therapeutics is more attractive than Janux Therapeutics.

Janux Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Spero Therapeutics has a beta of 0.591, suggesting its less volatile than the S&P 500 by 40.892%.

Janux Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Spero Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Janux Therapeutics pays -- of its earnings as a dividend. Spero Therapeutics pays out -- of its earnings as a dividend.

Janux Therapeutics quarterly revenues are $439K, which are smaller than Spero Therapeutics quarterly revenues of $7.8M. Janux Therapeutics's net income of -$28.1M is lower than Spero Therapeutics's net income of -$17.1M. Notably, Janux Therapeutics's price-to-earnings ratio is -- while Spero Therapeutics's PE ratio is 11.72x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Janux Therapeutics is 216.51x versus 0.56x for Spero Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Vir Biotechnology has a net margin of -6391.57% compared to Janux Therapeutics's net margin of -73950.52%. Janux Therapeutics's return on equity of -11.37% beat Vir Biotechnology's return on equity of -35.62%.

Janux Therapeutics has a consensus price target of --, signalling upside risk potential of 66.1%. On the other hand Vir Biotechnology has an analysts' consensus of $31.25 which suggests that it could grow by 299.73%. Given that Vir Biotechnology has higher upside potential than Janux Therapeutics, analysts believe Vir Biotechnology is more attractive than Janux Therapeutics.

Janux Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Vir Biotechnology has a beta of 0.492, suggesting its less volatile than the S&P 500 by 50.783%.

Janux Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vir Biotechnology offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Janux Therapeutics pays -- of its earnings as a dividend. Vir Biotechnology pays out -- of its earnings as a dividend.

Janux Therapeutics quarterly revenues are $439K, which are larger than Vir Biotechnology quarterly revenues of $289K. Janux Therapeutics's net income of -$28.1M is higher than Vir Biotechnology's net income of -$213.7M. Notably, Janux Therapeutics's price-to-earnings ratio is -- while Vir Biotechnology's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Janux Therapeutics is 216.51x versus 16.14x for Vir Biotechnology. Usually stocks with elevated PS ratios are considered overvalued.